A review of current evidence for vilazodone in major depressive disorder

Sheng Min Wang, Changsu Han, Soo Jung Lee, Ashwin A. Patkar, Prakash S. Masand, Chi Un Pae

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Objectives. This review is to inform clinicians of currently available data on vilazodone for treating patients with major depressive disorder (MDD), focusing on its diff erential action mechanism and extended clinical utility. Methods. A data search was conducted in June 2012 using the PubMed/MEDLINE/ relevant clinical trial databases with the key terms "vilazodone" or "Viibryd." Results. The effi cacy, safety, and tolerability of vilazodone have been demonstrated in two pivotal 8-week, randomized, double-blinded, placebo-controlled studies. Certain pharmacological characteristics of vilazodone were observed, including early onset of action, fewer sexual side eff ects, the absence of known cardiac toxicity, and minimal eff ect on weight gain, that may provide potential clinical advantages compared with currently available antidepressants. However, such possibilities should be replicated and confirmed in more well-designed and adequately powered clinical trials. Vilazodone requires dose titration up to 2 weeks to reach a target dose of 40 mg/d due to high rate of gastrointestinal side eff ects. No direct comparative studies with other antidepressants are currently available to confi rm the aforementioned potential clinical utility. Conclusion. Vilazodone is a newer antidepressant possessing diff erent action mechanisms compared to currently available antidepressants but whether it has superiority to other class of antidepressants in terms of effi cacy and safety should still warrant further evaluation through more well-controlled and direct comparison clinical trials.

Original languageEnglish
Pages (from-to)160-169
Number of pages10
JournalInternational Journal of Psychiatry in Clinical Practice
Volume17
Issue number3
DOIs
Publication statusPublished - 2013 Jan 1

Fingerprint

Major Depressive Disorder
Antidepressive Agents
Clinical Trials
Safety
Vilazodone Hydrochloride
PubMed
MEDLINE
Weight Gain
Placebos
Databases
Pharmacology

Keywords

  • Action mechanism
  • Antidepressant
  • Major depressive disorder
  • Vilazodone

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

A review of current evidence for vilazodone in major depressive disorder. / Wang, Sheng Min; Han, Changsu; Lee, Soo Jung; Patkar, Ashwin A.; Masand, Prakash S.; Pae, Chi Un.

In: International Journal of Psychiatry in Clinical Practice, Vol. 17, No. 3, 01.01.2013, p. 160-169.

Research output: Contribution to journalArticle

Wang, Sheng Min ; Han, Changsu ; Lee, Soo Jung ; Patkar, Ashwin A. ; Masand, Prakash S. ; Pae, Chi Un. / A review of current evidence for vilazodone in major depressive disorder. In: International Journal of Psychiatry in Clinical Practice. 2013 ; Vol. 17, No. 3. pp. 160-169.
@article{56db3c2924e545b49fd24af39d28fec5,
title = "A review of current evidence for vilazodone in major depressive disorder",
abstract = "Objectives. This review is to inform clinicians of currently available data on vilazodone for treating patients with major depressive disorder (MDD), focusing on its diff erential action mechanism and extended clinical utility. Methods. A data search was conducted in June 2012 using the PubMed/MEDLINE/ relevant clinical trial databases with the key terms {"}vilazodone{"} or {"}Viibryd.{"} Results. The effi cacy, safety, and tolerability of vilazodone have been demonstrated in two pivotal 8-week, randomized, double-blinded, placebo-controlled studies. Certain pharmacological characteristics of vilazodone were observed, including early onset of action, fewer sexual side eff ects, the absence of known cardiac toxicity, and minimal eff ect on weight gain, that may provide potential clinical advantages compared with currently available antidepressants. However, such possibilities should be replicated and confirmed in more well-designed and adequately powered clinical trials. Vilazodone requires dose titration up to 2 weeks to reach a target dose of 40 mg/d due to high rate of gastrointestinal side eff ects. No direct comparative studies with other antidepressants are currently available to confi rm the aforementioned potential clinical utility. Conclusion. Vilazodone is a newer antidepressant possessing diff erent action mechanisms compared to currently available antidepressants but whether it has superiority to other class of antidepressants in terms of effi cacy and safety should still warrant further evaluation through more well-controlled and direct comparison clinical trials.",
keywords = "Action mechanism, Antidepressant, Major depressive disorder, Vilazodone",
author = "Wang, {Sheng Min} and Changsu Han and Lee, {Soo Jung} and Patkar, {Ashwin A.} and Masand, {Prakash S.} and Pae, {Chi Un}",
year = "2013",
month = "1",
day = "1",
doi = "10.3109/13651501.2013.794245",
language = "English",
volume = "17",
pages = "160--169",
journal = "International Journal of Psychiatry in Clinical Practice",
issn = "1365-1501",
publisher = "Informa Healthcare",
number = "3",

}

TY - JOUR

T1 - A review of current evidence for vilazodone in major depressive disorder

AU - Wang, Sheng Min

AU - Han, Changsu

AU - Lee, Soo Jung

AU - Patkar, Ashwin A.

AU - Masand, Prakash S.

AU - Pae, Chi Un

PY - 2013/1/1

Y1 - 2013/1/1

N2 - Objectives. This review is to inform clinicians of currently available data on vilazodone for treating patients with major depressive disorder (MDD), focusing on its diff erential action mechanism and extended clinical utility. Methods. A data search was conducted in June 2012 using the PubMed/MEDLINE/ relevant clinical trial databases with the key terms "vilazodone" or "Viibryd." Results. The effi cacy, safety, and tolerability of vilazodone have been demonstrated in two pivotal 8-week, randomized, double-blinded, placebo-controlled studies. Certain pharmacological characteristics of vilazodone were observed, including early onset of action, fewer sexual side eff ects, the absence of known cardiac toxicity, and minimal eff ect on weight gain, that may provide potential clinical advantages compared with currently available antidepressants. However, such possibilities should be replicated and confirmed in more well-designed and adequately powered clinical trials. Vilazodone requires dose titration up to 2 weeks to reach a target dose of 40 mg/d due to high rate of gastrointestinal side eff ects. No direct comparative studies with other antidepressants are currently available to confi rm the aforementioned potential clinical utility. Conclusion. Vilazodone is a newer antidepressant possessing diff erent action mechanisms compared to currently available antidepressants but whether it has superiority to other class of antidepressants in terms of effi cacy and safety should still warrant further evaluation through more well-controlled and direct comparison clinical trials.

AB - Objectives. This review is to inform clinicians of currently available data on vilazodone for treating patients with major depressive disorder (MDD), focusing on its diff erential action mechanism and extended clinical utility. Methods. A data search was conducted in June 2012 using the PubMed/MEDLINE/ relevant clinical trial databases with the key terms "vilazodone" or "Viibryd." Results. The effi cacy, safety, and tolerability of vilazodone have been demonstrated in two pivotal 8-week, randomized, double-blinded, placebo-controlled studies. Certain pharmacological characteristics of vilazodone were observed, including early onset of action, fewer sexual side eff ects, the absence of known cardiac toxicity, and minimal eff ect on weight gain, that may provide potential clinical advantages compared with currently available antidepressants. However, such possibilities should be replicated and confirmed in more well-designed and adequately powered clinical trials. Vilazodone requires dose titration up to 2 weeks to reach a target dose of 40 mg/d due to high rate of gastrointestinal side eff ects. No direct comparative studies with other antidepressants are currently available to confi rm the aforementioned potential clinical utility. Conclusion. Vilazodone is a newer antidepressant possessing diff erent action mechanisms compared to currently available antidepressants but whether it has superiority to other class of antidepressants in terms of effi cacy and safety should still warrant further evaluation through more well-controlled and direct comparison clinical trials.

KW - Action mechanism

KW - Antidepressant

KW - Major depressive disorder

KW - Vilazodone

UR - http://www.scopus.com/inward/record.url?scp=84883186520&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84883186520&partnerID=8YFLogxK

U2 - 10.3109/13651501.2013.794245

DO - 10.3109/13651501.2013.794245

M3 - Article

C2 - 23578403

AN - SCOPUS:84883186520

VL - 17

SP - 160

EP - 169

JO - International Journal of Psychiatry in Clinical Practice

JF - International Journal of Psychiatry in Clinical Practice

SN - 1365-1501

IS - 3

ER -